|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 469.34 USD | -1.84% |
|
+2.77% | +3.52% |
| 03-11 | Vertex Pharmaceuticals Incorporated Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:30 AM | |
| 03-10 | US Equity Markets Mixed Amid Volatility, Crude Oil Price Rebound | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 13.79 | 17.33 | 13.17 | 12.14 | 12.16 | |||||
Return on Total Capital | 16.78 | 21.15 | 16.22 | 15.03 | 15.08 | |||||
Return On Equity % | 24.93 | 27.67 | 22.99 | -3.15 | 22.54 | |||||
Return on Common Equity | 24.93 | 27.67 | 22.99 | -3.15 | 22.54 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 47.78 | 59.6 | 55.16 | 53.17 | 53.66 | |||||
SG&A Margin | 11.09 | 10.58 | 11.52 | 13.29 | 14.61 | |||||
EBITDA Margin % | 38.35 | 50.69 | 45.36 | 41.53 | 40.55 | |||||
EBITA Margin % | 36.69 | 49.03 | 43.66 | 40.06 | 39.23 | |||||
EBIT Margin % | 36.69 | 49.03 | 43.65 | 39.88 | 39.06 | |||||
Income From Continuing Operations Margin % | 30.92 | 37.2 | 36.68 | -4.86 | 32.94 | |||||
Net Income Margin % | 30.92 | 37.2 | 36.68 | -4.86 | 32.94 | |||||
Net Avail. For Common Margin % | 30.92 | 37.2 | 36.68 | -4.86 | 32.94 | |||||
Normalized Net Income Margin | 22.36 | 31.16 | 30.8 | 27.71 | 26.92 | |||||
Levered Free Cash Flow Margin | 22.53 | 37.03 | 35.57 | 25.4 | 21.44 | |||||
Unlevered Free Cash Flow Margin | 23.04 | 37.42 | 35.85 | 25.58 | 21.51 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.6 | 0.57 | 0.48 | 0.49 | 0.5 | |||||
Fixed Assets Turnover | 5.59 | 6.2 | 6.79 | 5.46 | 4.24 | |||||
Receivables Turnover (Average Receivables) | 7.49 | 6.93 | 6.57 | 6.95 | 6.54 | |||||
Inventory Turnover (Average Inventory) | 12.48 | 8.87 | 7.38 | 5.31 | 3.85 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.46 | 4.83 | 3.99 | 2.69 | 2.9 | |||||
Quick Ratio | 4.04 | 4.46 | 3.6 | 2.17 | 2.24 | |||||
Operating Cash Flow to Current Liabilities | 1.23 | 1.51 | 1 | -0.14 | 0.94 | |||||
Days Sales Outstanding (Average Receivables) | 48.73 | 52.7 | 55.58 | 52.69 | 55.83 | |||||
Days Outstanding Inventory (Average Inventory) | 29.25 | 41.16 | 49.47 | 68.94 | 94.92 | |||||
Average Days Payable Outstanding | 15.86 | 24.51 | 25.95 | 25.3 | 26.42 | |||||
Cash Conversion Cycle (Average Days) | 62.11 | 69.36 | 79.09 | 96.33 | 124.33 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 9.58 | 6.47 | 4.6 | 10.66 | 10.91 | |||||
Total Debt / Total Capital | 8.74 | 6.07 | 4.4 | 9.63 | 9.83 | |||||
LT Debt/Equity | 8.78 | 5.82 | 4.12 | 10.1 | 10.46 | |||||
Long-Term Debt / Total Capital | 8.02 | 5.47 | 3.94 | 9.13 | 9.43 | |||||
Total Liabilities / Total Assets | 24.81 | 23.35 | 22.66 | 27.18 | 27.21 | |||||
EBIT / Interest Expense | 45.19 | 79.9 | 97.68 | 143.63 | 352.44 | |||||
EBITDA / Interest Expense | 47.77 | 83.2 | 102.54 | 154.34 | 384.26 | |||||
(EBITDA - Capex) / Interest Expense | 43.95 | 79.46 | 98 | 144.61 | 351.35 | |||||
Total Debt / EBITDA | 0.33 | 0.2 | 0.18 | 0.37 | 0.4 | |||||
Net Debt / EBITDA | -2.23 | -2.17 | -2.85 | -2.01 | -2.01 | |||||
Total Debt / (EBITDA - Capex) | 0.36 | 0.21 | 0.19 | 0.4 | 0.44 | |||||
Net Debt / (EBITDA - Capex) | -2.43 | -2.27 | -2.99 | -2.14 | -2.2 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 22.06 | 17.91 | 10.51 | 11.66 | 8.9 | |||||
Gross Profit, 1 Yr. Growth % | -0.57 | 12.48 | 2.27 | 7.63 | 9.92 | |||||
EBITDA, 1 Yr. Growth % | -2.49 | 12.66 | -1.1 | 2.23 | 6.31 | |||||
EBITA, 1 Yr. Growth % | -3.15 | 12.49 | -1.58 | 2.46 | 6.62 | |||||
EBIT, 1 Yr. Growth % | -3.15 | 12.49 | -1.62 | 2.03 | 6.65 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -13.63 | 41.84 | 8.96 | -114.8 | -838.09 | |||||
Net Income, 1 Yr. Growth % | -13.63 | 41.84 | 8.96 | -114.8 | -838.09 | |||||
Normalized Net Income, 1 Yr. Growth % | -3.83 | 16.45 | 9.22 | 0.48 | 5.79 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -12.44 | 42.29 | 8.35 | -114.97 | -836.54 | |||||
Accounts Receivable, 1 Yr. Growth % | 28.39 | 26.86 | 8.4 | 2.94 | 27.55 | |||||
Inventory, 1 Yr. Growth % | 25.75 | 30.44 | 60.4 | 63.16 | 39.94 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 10.93 | 2.2 | -0.2 | 77.89 | 19.28 | |||||
Total Assets, 1 Yr. Growth % | 14.3 | 35.13 | 25.23 | -0.87 | 13.8 | |||||
Tangible Book Value, 1 Yr. Growth % | 19.4 | 40.51 | 28.08 | -7.39 | 18.34 | |||||
Common Equity, 1 Yr. Growth % | 16.27 | 37.75 | 26.36 | -6.66 | 13.75 | |||||
Cash From Operations, 1 Yr. Growth % | -18.75 | 56.23 | -14.35 | -113.93 | -837.19 | |||||
Capital Expenditures, 1 Yr. Growth % | -9.55 | -12.89 | -2.1 | 48.55 | 46.99 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -19.37 | 37.68 | 6.13 | -20.24 | -8.09 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -18.94 | 36.92 | 5.86 | -20.32 | -8.42 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 34.89 | 19.96 | 14.15 | 11.08 | 10.27 | |||||
Gross Profit, 2 Yr. CAGR % | 39.47 | 17.98 | 7.26 | 4.92 | 8.77 | |||||
EBITDA, 2 Yr. CAGR % | 48.97 | 19.62 | 5.56 | 0.55 | 4.25 | |||||
EBITA, 2 Yr. CAGR % | 52.05 | 19.74 | 5.22 | 0.42 | 4.52 | |||||
EBIT, 2 Yr. CAGR % | 52.05 | 19.74 | 5.2 | 0.19 | 4.32 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 41.08 | 10.68 | 24.32 | -59.85 | 4.51 | |||||
Net Income, 2 Yr. CAGR % | 41.08 | 10.68 | 24.32 | -59.85 | 4.51 | |||||
Normalized Net Income, 2 Yr. CAGR % | 50.17 | 21.77 | 12.78 | 4.75 | 3.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 41.34 | 11.62 | 24.16 | -59.72 | 5.02 | |||||
Accounts Receivable, 2 Yr. CAGR % | 33.96 | 27.63 | 17.27 | 5.64 | 14.59 | |||||
Inventory, 2 Yr. CAGR % | 45.19 | 28.07 | 44.65 | 61.77 | 51.1 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.74 | 6.48 | 1 | 33.24 | 45.67 | |||||
Total Assets, 2 Yr. CAGR % | 27.07 | 24.28 | 30.08 | 11.42 | 6.21 | |||||
Tangible Book Value, 2 Yr. CAGR % | 36.28 | 29.52 | 34.15 | 8.91 | 4.69 | |||||
Common Equity, 2 Yr. CAGR % | 28.83 | 26.55 | 31.93 | 8.6 | 3.04 | |||||
Cash From Operations, 2 Yr. CAGR % | 29.79 | 12.67 | 15.68 | -65.46 | 1.32 | |||||
Capital Expenditures, 2 Yr. CAGR % | 76.54 | -11.24 | -7.65 | 20.6 | 47.77 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 34.98 | 21.74 | 20.88 | -8 | -14.38 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 33.91 | 21.38 | 20.39 | -8.16 | -14.58 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 35.46 | 28.97 | 16.72 | 13.31 | 10.35 | |||||
Gross Profit, 3 Yr. CAGR % | 43.62 | 41.96 | 12.49 | 7.38 | 6.56 | |||||
EBITDA, 3 Yr. CAGR % | 58 | 51.23 | 12.27 | 4.44 | 2.44 | |||||
EBITA, 3 Yr. CAGR % | 61.16 | 53.86 | 12.16 | 4.29 | 2.45 | |||||
EBIT, 3 Yr. CAGR % | 61.16 | 53.86 | 12.15 | 4.13 | 2.3 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 3.92 | 41.33 | 10.1 | -38.85 | 5.97 | |||||
Net Income, 3 Yr. CAGR % | 3.76 | 41.33 | 10.1 | -38.85 | 5.97 | |||||
Normalized Net Income, 3 Yr. CAGR % | 61.6 | 54.74 | 17.43 | 8.52 | 5.1 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 3.66 | 41.66 | 10.52 | -38.66 | 6.12 | |||||
Accounts Receivable, 3 Yr. CAGR % | 40.52 | 31.55 | 20.87 | 12.29 | 12.49 | |||||
Inventory, 3 Yr. CAGR % | 41.6 | 40.1 | 38.05 | 50.57 | 54.14 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.6 | 20.44 | 4.2 | 21.97 | 28.42 | |||||
Total Assets, 3 Yr. CAGR % | 29.08 | 29.7 | 24.59 | 18.82 | 12.21 | |||||
Tangible Book Value, 3 Yr. CAGR % | 25.65 | 37.68 | 29.04 | 18.56 | 11.96 | |||||
Common Equity, 3 Yr. CAGR % | 31.56 | 31.74 | 26.49 | 17.56 | 10.29 | |||||
Cash From Operations, 3 Yr. CAGR % | 27.67 | 38.06 | 2.83 | -42.88 | -4.2 | |||||
Capital Expenditures, 3 Yr. CAGR % | 35.03 | 39.5 | -8.29 | 8.2 | 28.82 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 24.35 | 52.29 | 16.3 | 5.24 | -8.03 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 23.22 | 50.87 | 15.97 | 4.92 | -8.24 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 34.79 | 29.12 | 26.49 | 21.5 | 14.1 | |||||
Gross Profit, 5 Yr. CAGR % | 52.14 | 43.04 | 34.83 | 25.79 | 10.99 | |||||
EBITDA, 5 Yr. CAGR % | 109.14 | 58.38 | 43.48 | 28.45 | 8.99 | |||||
EBITA, 5 Yr. CAGR % | 201.27 | 61.97 | 45.36 | 29.72 | 9.04 | |||||
EBIT, 5 Yr. CAGR % | 201.27 | 61.97 | 45.35 | 29.6 | 8.95 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 94.55 | 105.05 | 11.64 | -14.57 | 7.83 | |||||
Net Income, 5 Yr. CAGR % | 83.67 | 66.01 | 11.54 | -14.57 | 7.83 | |||||
Normalized Net Income, 5 Yr. CAGR % | 89.49 | 48.69 | 49.92 | 32.38 | 11.47 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 81.3 | 65.28 | 11.42 | -14.34 | 8.29 | |||||
Accounts Receivable, 5 Yr. CAGR % | 41.51 | 38.66 | 30.71 | 20.5 | 18.32 | |||||
Inventory, 5 Yr. CAGR % | 35.4 | 32.73 | 42.81 | 48.4 | 43.13 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 15.32 | 13.02 | 12.34 | 25.41 | 19.14 | |||||
Total Assets, 5 Yr. CAGR % | 35.91 | 38.62 | 29.48 | 22.06 | 16.89 | |||||
Tangible Book Value, 5 Yr. CAGR % | 60.3 | 44.36 | 28.98 | 25.35 | 18.68 | |||||
Common Equity, 5 Yr. CAGR % | 54.25 | 46.98 | 31.71 | 21.94 | 16.53 | |||||
Cash From Operations, 5 Yr. CAGR % | 62.11 | 37.35 | 22.73 | -20.68 | 2.22 | |||||
Capital Expenditures, 5 Yr. CAGR % | 32.96 | 15.54 | 15.99 | 31.61 | 10.99 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 50.22 | 49.31 | 31.66 | 24.48 | 2.89 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 44.82 | 46.87 | 30.56 | 23.7 | 2.62 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















